Research Report
Company Analysis
SK Biopharmaceuticals (326030 KS/Buy)Solid earnings; adding a second product could unlock further upside
- Author Seung-min Kim
- Date Fri Aug 07 00:00:00 KST 2026
- Stock Code 326030
- File 20260807_SK Biopharmaceuticals (326030 KS_Buy).pdf
also increased 2.2% QoQ to US$1,043, suggesting that the strong performance was supported not only by increased prescriptions but also by improved net pricing and/or favorable channel inventory effects.
Contact Us
- Office number1588-6800
-
- Investor Relationsirteam@miraeasset.com
- Human Resourcerecruit@miraeasset.com
- AddressMirae Asset CENTER1 Bldg, East Tower, 26, Euljiro 5 gil, Jung-gu, Seoul 100-210
Family Websites of Mirae Asset Financial Groupopen
Korea (Headquarters)
Greece
Luxembourg
- Mirae Asset Global Investment(SICAV)
Mongolia
USA
- Mirae Asset Securities &
Investments Mirae Asset Securities(NY)
- Mirae Asset Global Investments
- Global X
- Mirae Asset Capital Life Science
- Wealthspot
Vietnam
- Mirae Asset Securities
- Mirae Asset Finance Company
- Mirae Asset Prevoir Life Insurance
- Mirae Asset Global Investments
- Vina Digital Finance Platform
- Grooo International Joint Stock
Company Mirae Asset Alternative
Invetment VietnamMirae Asset Securities
- Ho Chi Minh representative Ofiice
Brazil
Singapore
United Arab Emirates
Mirae Asset Investment Managers
- Dubai representative Office
Ireland
United Kingdom
India
Indonesia
Japan
China
- Mirae Asset Huachen Fund
Management Mirae Asset Investment
Management(Shanghai)Mirae Asset Securitires
(Beijing representative Office)Mirae Asset Securitires
(Shanghai representative Office)
Canada
Colombia
Australia
Hong Kong SAR*
Germany
Global X ETFs - Germany Rep Office
Italy
Global X ETFs - Italy Rep Office
* Special Administrative Region of the People’s Republic of China